Cardinal Health, IncNYSE: CAH
Health Care · Health Care Distributors
$223.87
+11.59%
Vol: 331K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Cardinal Health raises FY26 guidance and dividend, and partners with Shine Technologies on domestic radiopharmaceutical productionPositive▶
Cardinal Health's Board approved a quarterly dividend increase to $0.5158 per share on May 5. On the same day, the company announced a partnership with Shine Technologies to scale domestic production of radiopharmaceuticals. Cardinal raised FY26 adjusted EPS guidance to $10.70-$10.80 (from $10.15-$10.35) and lifted free cash flow view to $3.3B-$3.7B (from $3.0B-$3.5B), while lowering its FY26 tax rate to 19% from 21-23%. The company released its 2026 Advanced Therapies Report focused on community-based care delivery. Following Q3 fiscal results on April 30 that delivered 11% revenue and 35% adjusted EPS growth (but slight revenue miss), JPMorgan trimmed its PT to $215 from $243. Analyst consensus across 17 analysts remains Strong Buy with an average PT of $245.27.
May 20Cardinal Health expanded domestic radiopharmaceutical production with Shine Technologies on May 5 and raised its quarterly dividend to $0.5158/share, while JPMorgan trimmed its price target to $215 from $243.Mixed▶
Cardinal Health announced an Ac-225 radiopharmaceutical production capacity expansion with Shine Technologies on May 5 to meet growing demand for novel cancer therapies. The board approved a quarterly dividend hike to $0.5158/share the same day. However, JPMorgan analyst Lisa Gill cut her price target to $215 from $243 (Neutral) following a Q3 print where revenue came in slightly below FactSet consensus and shares fell 7% intraday on April 30. The company has projected 30% adjusted EPS growth for FY2026 despite a 9.4% YTD decline. Risk: revenue softness despite EPS beats suggests margin-driven growth that may face limits as analyst targets reset lower.
May 19Cardinal Health shares rose 4.3% as investors digested dividend increase and Shine Technologies radiopharmaceutical partnership.Positive▶
Cardinal Health raised its quarterly dividend to $0.5158 per share on May 5, 2026. The same day, Cardinal and Shine Technologies announced plans to ramp domestic production of radiopharmaceuticals. Shares rose 4.3% to $194.38 on May 14, 2026. Q3 FY26 had delivered 11% revenue and 35% adjusted EPS growth. Morgan Stanley issued a Buy on May 5; JPMorgan lowered PT to $215 from $243 on May 4. Mean PT $245.27 implies 22.78% upside. Bear case: Pharma segment slightly missed FactSet consensus, and regulatory/pricing pressures persist.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Cardinal Health presented at BofA Healthcare Conference May 13; JPMorgan set $215 PT on May 4 after FY26 EPS guide raised to $10.70-$10.80.Positive▶
Cardinal Health presented at the Bank of America Global Healthcare Conference on May 13, with CFO Aaron Alt highlighting raised full-year FY2026 non-GAAP EPS guidance to $10.70-$10.80. Q3 FY2026 results showed revenue up 11% to $61B and gross profit up 18% to $2.5B, with adjusted EPS of $3.17 beating estimates by $0.38. JPMorgan provided a $215 price target on May 4 with a Neutral rating, while TD Cowen raised its target to $255 from $251 on May 1 with a Buy. Baird lowered its target to $248 from $257 on May 1 maintaining Outperform. The company also released its 2026 Advanced Therapies Report on community-based care. Risk: pharma distribution margin pressure and Optum/Express Scripts dynamics.
May 14Cardinal Health presents at BofA Healthcare Conference and partners with Shine on US radiopharmaceutical production amid mixed analyst viewsMixed▶
On May 13, 2026, Cardinal Health presented at the Bank of America Global Healthcare Conference with CFO Aaron Alt and VP of IR Dave Frost. On May 5, Cardinal Health and Shine Technologies announced a partnership to scale up domestic production of radiopharmaceuticals, expanding Cardinal's specialty distribution capabilities. The company also released its 2026 Advanced Therapies Report on shifting community-based care delivery. Analyst views are mixed: JPMorgan lowered its price target to $215 from $243 on May 4, while Morgan Stanley issued a Buy rating on May 5. Shares trade near $185.92 (market cap ~$43.66B), down 9.4% over six months despite $250.7B in trailing revenue. Analyst targets range from $215 to $275.
May 13Cardinal Health board approves quarterly dividend increase to $0.5158 per share on May 5 alongside expanded radiopharmaceutical production with Shine Technologies.Positive▶
On May 5, 2026, Cardinal Health's Board of Directors approved an increase to its quarterly dividend to $0.5158 per share. The same day, Cardinal Health and Shine Technologies announced expanded domestic production of actinium-225, a radionuclide used for cancer treatment, at a facility in Indianapolis. Morgan Stanley issued a Buy rating on May 5, while JPMorgan had lowered its price target to $215 from $243 on May 4. The company also released its 2026 Advanced Therapies Report focusing on the shift toward community-based care. Shares were trading around $182.84 with analysts seeing roughly 15% upside.
May 12Cardinal Health shares sold by Swiss Life as JP Morgan sets $215 PT following Q3 FY26 EPS beat and raised guidancePositive▶
Cardinal Health reported Q3 FY26 EPS of $3.17 (vs $2.79 consensus) on April 30, beating profit but missing revenue ($60.94B vs $62.10B est.). Management raised FY26 adjusted EPS guidance to $10.70-$10.80 (from $10.15-$10.35). On May 1, TD Cowen raised PT to $255 (Buy); Citigroup trimmed PT to $245 (Buy). JP Morgan set a $215 PT on May 4. Swiss Life Asset Management disclosed reducing its CAH stake by 9.6%. Board increased quarterly dividend to $0.5158 per share, payable July 15.
May 11Cardinal Health raises FY26 EPS guidance to $10.70-$10.80, boosts dividend, partners with Shine Tech on radiopharmaceutical productionPositive▶
Cardinal Health raised its full-year 2026 adjusted EPS guidance to $10.70-$10.80, well ahead of Street estimates of $10.31, after Q3 FY26 delivered 11% revenue growth and 35% adjusted EPS growth. The Board approved an increase in the quarterly dividend to $0.5158 per share on May 5. On the same day, Cardinal Health announced a partnership with Shine Technologies to expand domestic radiopharmaceutical production. The company released its 2026 Advanced Therapies Report highlighting community-based care delivery. Stock declined 14.1% over the past month and traded down 7% intraday April 30 after Q3 revenue came in slightly below FactSet consensus, but analysts see rebound potential with a Zacks Rank #2 (Buy). JPMorgan set a $215 price target on May 4. Stock is at $197 as of May 5.
May 8Cardinal Health Q1 beats guidance; dividend hike, biosimilar savings highlightedPositive▶
Cardinal Health reported Q1 FY2026 revenue of $64.0B (+22% YoY), with GAAP EPS of $1.88 (+11%) and non-GAAP EPS surging 36% to $2.55. Company raised FY2026 non-GAAP EPS guidance to $9.65–$9.85 (+17%–20%) and adjusted free cash flow to $3.0–$3.5B. Acquired Solaris Health (leading urology MSO) on Nov 3, 2025, adding 750+ providers across 250+ locations in 14 states. Released 2026 Biosimilars Report highlighting $56B in U.S. savings since 2015, projecting $181B future savings. Board increased quarterly dividend to $0.5158/share, reflecting confidence. Price target raised to $255. Wall Street Zen upgraded to "Strong Buy" May 2. Analyst consensus "Buy" with mixed near-term technicals (-6.86% monthly) offset by long-term value in healthcare services expansion.
May 7Cardinal Health raises FY26 EPS guidance to $10.15-10.35 (+23-26% growth); acquires Solaris Health, expands Ac-225 productionPositive▶
Cardinal Health reported Q2 FY26 revenue of $65.6B, up 19% YoY. Adjusted EPS beat with strong performance lifting outlook. Company raised FY26 adjusted EPS guidance to $10.15-10.35 range (+23-26% growth). Acquired Solaris Health (leading urology MSO with 750+ providers). Expanded Actinium-225 production capacity at Indianapolis facility, quadrupling weekly output since end of 2024. Quarterly dividend raised to $0.5158 per share, payable July 15. FY26 adjusted free cash flow guidance $2.75-3.25B. Stock at $192.10 with 27% one-year return. Strong positioning in specialty pharma and healthcare services.
May 6Cardinal Health Q1 revenue beats $60.94B despite missing forecast; raises FY26 EPS guidance to $10.75Mixed▶
Cardinal Health reported Q1 revenue of $60.94B (+11% YoY) with adjusted EPS of $3.17 beating $2.79 consensus, though overall revenue missed expectations. Company approved quarterly dividend increase to $0.5158 per share and expanded Actinium-225 nuclear therapy production in Indianapolis. GLP-1 drug demand surged 30%+ revenue growth; analysts viewed post-earnings sell-off as overreaction despite tariff and pricing regulatory headwinds ahead.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| MCKMCKESSON | $773.91 | +0.97% | -1.2% | 15.2x | 0.35 | $92.1B |
| CORCENCORA | $280.20 | +5.56% | +1.4% | 13.4x | 0.65 | $51.6B |
| CAHCARDINAL | $223.87 | +11.59% | +0.4% | 16.8x | 0.54 | $47.0B |
| HSICHENRY | $81.88 | +11.40% | +1.1% | 12.4x | 0.82 | $8.4B |
| LLYELI | $1,119.42 | +7.47% | +5.4% | 23.4x | 0.48 | $928.9B |
| JNJJOHNSON | $237.09 | +2.31% | +1.2% | 18.2x | 0.26 | $557.8B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.